Sanofi

Investors

We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.

A technologist, wearing purple glove and safety glasses performing structural analysis by HDX-MS, handling samples with precision.

First quarter 2026

Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.

Press Releases


June 19, 2026
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

June 19, 2026
Communiqué de presse : Sanofi et HEC Paris lancent la « Sanofi MBA Life Sciences Scholarship » pour accompagner les futurs leaders de la santé

June 12, 2026
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

Upcoming Events

18Jun

2026

JPM European Healthcare Forum l London

Conferences


30Jul

2026

Second quarter 2026 results

Second quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on July 30, 2026. The presentation will be followed by a Q&A session.

13:00 - 14:15 CET (7:00am - 8:15am EST)

Quarterly results


9Sep

2026

Kepler Cheuvreux Autumn Conference l Paris

Speaker : Thomas Grenier, Head of North America, Vaccines

Conferences


Female scientist in white lab coat and safety equipment working with a tablet at a laboratory workstation with protective hood
Shuang Yang, Scientist, China

2025 20-F

Presenting our 2025 FORM 20-F.

Sanofi's dividends until 2025

31st Consecutive Year of Dividend Increase ​

Dr. Yohana Mokiwa has a serious expression, blue shirt and stethoscope, as he speaks with a patient in a pop up clinic
Dr. Yohana Mokiwa speaking with a patient in a pop-up clinic, Dar es Salaam, Tanzania

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.

Contact Our Investor Relations Team

For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00